1. Brunetto MR, Marcellin P, Bonino F et al. HBsAg decline in HBeAg-negative patients treated with peginterferon alfa-2a is associated with sustained response up to 5 years post-treatment: patients with continuous HBsAg decline starting before week 24 achieve highest rates of response. Hepatology 2009; (S4): 519A Abstract 452.
2. Moucari R, Bourlière M, Ripault M-P et al. HBsAg decline in chronic hepatitis B patients treated with potent NUCS. Hepatology 2009; (S4): 507A Abstract 426.
3. Hadziyannis E, Sevastianos V, Georgiou A et al. Treatment-related compared to spontaneously-occurring HBsAg loss in HBe-Ag-negative chronic hepatitis B. Hepatology 2009; (S4): 509A Abstract 431.
4. Lampertico P, Viganò M, Facchetti F et al. Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from a large multicenter cohort study in 376 patients. Hepatology 2009; (S4): 408A Abstract 220.
5. Marcellin P, Buti M, Krastev Z et al. Three years of Tenofovir Disoproxil Fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (Study 102); preliminary analysis. Hepatology 2009; (S4): 532A Abstract 481.
6. Wang Y, Thongsawat S, Gane EJ et al. Efficacy and safety outcomes after 4 years of Telbivudine treatment in patients with chronic hepatitis B (CHB). Hepatology 2009; (S4): 533A Abstract 482.
7. Petersen J, Lutgehetmann M, Zoulim F et al. Entecavir and Tenofovir combination therapy in chronic hepatitis B: rescue therapy in patients with advanced fibrosis and multiple previous treatment failures. Results from an international multicenter cohort study. Hepatology 2009; (S4): 496A Abstract 405.
8. Wong CR, Garcia RT, Trinh HN et al. Response to Tenofovir (TDF)-based combination therapy with Entecavir (ETV) or Emtricitabine (FTC) or Lamivudine (LAM) in patients with chronic hepatitis B (CHB) with antiviral resistance (AVR) or partial response (PR) to prior monotherapy. Hepatology 2009; (S4): 500A Abstract 412.
9. Reijinders JG, de Vries-Sluijs T, Hansen BE et al. Five years Tenofovir therapy is associated with maintained virologic response, but significant decline in renal function in HIV/HBV coinfected patients. Hepatology 2009; (S4): 506A Abstract 425.
10. Constable C, Childs K, Vachon M-L et al. Does Tenofovir increase the risk of abnormal bone and calcium metabolism? Hepatology 2009; (S4): 518A Abstract 451.